Genmab A/S

General Information

[Note (A public offering):  Currently, our ordinary shares are listed on Nasdaq Copenhagen A/S, or Nasdaq Copenhagen, under the symbol “GEN” and our ADSs are traded on the over-the-counter market in the United States under the symbol “GMXAY.”]

We are an international biotechnology company specializing in antibody therapeutics for the treatment of cancer and other diseases. Our core purpose is to improve the lives of patients by creating and developing innovative antibody products. Our vision is to transform cancer treatment by launching our own proprietary product by 2025 and advancing our pipeline of differentiated and well-tolerated antibodies. We are building and expanding our late-stage development and commercial capabilities to allow us to bring our proprietary products to market in the future. Today, we have a well-diversified portfolio of products, product candidates and technologies. Our portfolio includes two marketed partnered products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, or MM, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia, or CLL, in addition to a broad pipeline of differentiated product candidates.

Employees: 419
Founded: 1998
Contact Information
Address Kalvebod Brygge 43, 1560 Copenhagen V, Denmark
Phone Number +45 70 20 27 28.
Web Address
View Prospectus: Genmab A/S
Financial Information
Market Cap
Revenues $4389 mil (last 12 months)
Net Income $201.3 mil (last 12 months)
IPO Profile
Symbol GMAB
Exchange NASDAQ
Shares (millions): 28.5
Price range $17.75 - $17.75
Est. $ Volume $505.9 mil
Manager / Joint Managers BofA Merrill Lynch/ Morgan Stanley/ Jefferies
CO-Managers Guggenheim Securities/ RBC Capital Markets
Expected To Trade: 7/18/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change